Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease

被引:102
|
作者
Noguchi, M [1 ]
Hiwatashi, N [1 ]
Liu, Z [1 ]
Toyota, T [1 ]
机构
[1] Tohoku Univ, Sch Med, Dept Internal Med 3, Aoba Ku, Sendai, Miyagi 98077, Japan
关键词
Crohn's disease; inflammation; mucosal immunology; soluble TNF receptor; tumour necrosis factor; ulcerative colitis;
D O I
10.1136/gut.43.2.203
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background-Tumour necrosis factor (TNF) alpha and TNF-beta are soluble ligands binding to TNF receptors with similar activities; soluble TNF receptors neutralise TNF activity by acting as inhibitors. Little is known about the cytokine/soluble receptor role in inflammatory bowel disease (IBD). Aims-To test the hypothesis that an imbalance in secretion between TNF and TNF inhibitors plays a role in gut inflammation in patients with IBD. Methods-The secretion of TNF-alpha, TNF-beta, and soluble TNF receptors was compared in the culture supernatants of colonic biopsy specimens and isolated lamina propria mononuclear cells from patients with active colonic IBD. Results-Spontaneous secretion of TNF-alpha in involved IBD mucosa was higher than in normal control and self limited colitis mucosa. Secretion of TNF-beta was higher in patients with Crohn's disease than in those with ulcerative colitis. Soluble TNF receptor in IBD mucosa inhibited TNF activity. Type 2 soluble receptor release from IBD mucosa was increased in active inflammation; release from lamina propria cells was not increased. Mucosal TNF-alpha production correlated with severity of disease. Conclusions-Results showed enhanced secretion of TNF-alpha but failure to release enhanced amounts of soluble TNF receptor in lamina propria mononuclear cells of patients with IBD. An imbalance in secretion between TNF and TNF inhibitor may be implicated in the pathogenesis of IBD.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [41] Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents
    Karmiris, Konstantinos
    Bossuyt, Peter
    Sorrentino, Dario
    Moreels, Tom
    Scarcelli, Antonella
    Legido, Jesus
    Dotan, Iris
    Naismith, Graham D.
    Jussila, Airi
    Preiss, Jan C.
    Kruis, Wolfgang
    Li, Andy C. Y.
    Bouguen, Guillaume
    Yanai, Henit
    Steinwurz, Flavio
    Katsanos, Konstantinos H.
    Subramaniam, Kavitha
    Tarabar, Dino
    Zaganas, Ioannis V.
    Ben-Horin, Shomron
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (05): : 382 - 389
  • [42] Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease
    Biron, Amelie
    Beaugerie, Laurent
    Chazouilleres, Olivier
    Kirchgesner, Julien
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (05) : 857 - 868
  • [43] Simultaneous inhibition of α4/β7 integrin and tumour necrosis factor-α in concomitant spondyloarthritis and inflammatory bowel disease
    Richard, Nicolas
    Hazel, Elizabeth M.
    Haroon, Nigil
    Inman, Robert D.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (12)
  • [44] Altered immunoregulatory profile during anti-tumour necrosis factor treatment of patients with inflammatory bowel disease
    Grundstroem, J.
    Linton, L.
    Thunberg, S.
    Forsslund, H.
    Janczewska, I.
    Befrits, R.
    van Hage, M.
    Gafvelin, G.
    Eberhardson, M.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 169 (02): : 137 - 147
  • [45] A SINGLE-CELL THERAPEUTIC ATLAS OF ANTI-TUMOUR NECROSIS FACTOR THERAPY IN INFLAMMATORY BOWEL DISEASE
    Thomas, Tom
    Rich-Griffin, Charlotte
    Pohin, Mathilde
    Friedrich, Matthias
    Kulicke, Ruth
    Bielecki, Piotr
    Spies, Noah
    Travis, Simon P.
    Uhlig, Holm
    Dendrou, Calliope
    Buckley, Christopher D.
    GASTROENTEROLOGY, 2023, 164 (06) : S123 - S123
  • [46] Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease
    Lee, Ho-Su
    Jo, Kyung-Wook
    Shim, Tae Sun
    Song, Jin Woo
    Lee, Hyo Jeong
    Hwang, Sung Wook
    Park, Sang Hyoung
    Yang, Dong-Hoon
    Kim, Kyung-Jo
    Ye, Byong Duk
    Byeon, Jeong-Sik
    Myung, Seung-Jae
    Kim, Jin-Ho
    Yang, Suk-Kyun
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (11): : 1053 - 1057
  • [47] Predictors of Non-response or Loss of Response to Tumour Necrosis Factor Antagonist Therapies in Inflammatory Bowel Disease
    Khalid, Javaria Mona
    Peyrin-Biroulet, Laurent
    Armuzzi, Alessandro
    Gisbert, Javier P.
    Nguyen, Geoffrey
    Bokemeyer, Bernd
    Lindsay, James
    Smyth, Michael
    Munsaka, Melvin
    Ramagopalan, Sreeram
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S316 - S316
  • [48] Audit of the assessment, prevalence and treatment of osteoporosis in a single-centre cohort of patients with inflammatory bowel disease managed with tumour necrosis factor inhibitor treatment
    Cronin, O.
    Bell, S.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S426 - S427
  • [49] Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis
    Shihab, Zaid
    Yeomans, Neville D.
    De Cruz, Peter
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (08): : 979 - 988
  • [50] A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease
    Thomas, Pepijn W. A.
    Chin, Paul K. L.
    Barclay, Murray L.
    INTERNAL MEDICINE JOURNAL, 2021, 51 (03) : 341 - 347